Hylios
HomeIntelligencePricingResourcesNews
LoginFree daily briefStart a Pilot
Back to Intelligence

#emerging-therapies

(1 articles)
Trade Policy & Tariffs
High ImpactNov 4, 2026

BIS Defines Pharma Products Exempt from Section 232 Tariffs

The Bureau of Industry and Security has issued critical guidance defining which pharmaceutical products qualify for zero-tariff treatment under Section 232, addressing Presidential Proclamation 11020

Sandler, Travis & Rosenberg, P.A.#section-232-tariffs#pharmaceutical-tariffs#trade-policy

Hylios

Hylios - Better Decisions. Made Faster.

Newsletter

The daily supply chain brief, free. Unsubscribe any time.

Product

  • Features
  • Shipper Network Diagnostic
  • Deal Intelligence
  • Demand Intelligence
  • For Carriers
  • Tariff Exposure
  • Pricing
  • Design Partners
  • Documentation

Guides

  • Digital Twin Guide
  • Simulation Guide
  • Modeling Guide
  • Sandbox Guide
  • Intelligence Buyer's Guide
  • Hylios vs Alternatives
  • Methodology

Company

  • About
  • News
  • Careers

Legal

  • Privacy Policy
  • Terms of Service
© 2026 Hylios. All rights reserved.